|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||22.4599 - 22.5100|
|52 Week Range||18.2500 - 22.7000|
|PE Ratio (TTM)||264.23|
|Expense Ratio (net)||0.30%|
In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.
In 1H17, Teva Pharmaceutical's (TEVA) respiratory franchise reported revenues of ~$626 million, or ~8% lower YoY (year-over-year).
GlaxoSmithKline's (GSK) vaccine business includes meningitis vaccines, influenza vaccines, and the established vaccines in its portfolio.
Novartis is focused on integrated drug development as well as centralized operations, and its new organizational structure has proven to be beneficial.
Sanofi’s (SNY) established products contributed over 29.5% of its total revenue in 2Q17. Established product revenue, which fell 2.3% at constant exchange rates in 2Q17, stood at 2.6 billion euros. Lower…...
Analysts expect Novartis's 2Q17 revenues for Alcon to increase operationally following strong sales of products from the vision care franchise.
Novartis expects to absorb the impact of generic competition and expects its 2017 sales to be in line with its 2016 revenue at a constant exchange rate.